Late-stage immunotherapy company Immutep (ASX:IMM) has announced an upcoming poster presentation for the pivotal TACTI-004 Phase 3 trial.
The poster will be presented at the European Lung Cancer Congress (ELCC) 2025 in Paris from 26 to 29 March.
The trial-in-progress poster includes an overview and study design of the TACTI-004 Phase 3 evaluating the Immutep’s MHC Class2I agonist, eftilagimod alfa (efti) in combination with MSD’s KEYTRUDA (pembrolizumab) and chemotherapy as first-line therapy for patients with advanced or metastatic non-small cell lung cancer.
The global trial will enrol approximately 750 patients, regardless of PD-L1 expression, with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries.
Immutep chief scientific offcer Frédéric Triebel said, “We look forward to engaging with physicians in the lung cancer community at the ELCC conference to discuss our TACTI-004 Phase III study that is actively recruiting patients. Efti in combination with KEYTRUDA may change the treatment paradigm for patients with advanced or metastatic non-small cell lung cancer, irrespective of their PD-L1 expression, and we hope to see this registrational trial confirm the promising safety and efficacy achieved to date.”